These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31921215)

  • 1. ORF6 and ORF61 Expressing MVA Vaccines Impair Early but Not Late Latency in Murine Gammaherpesvirus MHV-68 Infection.
    Samreen B; Tao S; Tischer K; Adler H; Drexler I
    Front Immunol; 2019; 10():2984. PubMed ID: 31921215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model.
    El-Gogo S; Staib C; Meyr M; Erfle V; Sutter G; Adler H
    Vaccine; 2007 May; 25(20):3934-45. PubMed ID: 17433507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunization with recombinant adenoviral vectors expressing murine gammaherpesvirus-68 genes M2 and M3 can reduce latent viral load.
    Hoegh-Petersen M; Thomsen AR; Christensen JP; Holst PJ
    Vaccine; 2009 Nov; 27(48):6723-30. PubMed ID: 19748577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two kinetic patterns of epitope-specific CD8 T-cell responses following murine gammaherpesvirus 68 infection.
    Freeman ML; Lanzer KG; Cookenham T; Peters B; Sidney J; Wu TT; Sun R; Woodland DL; Sette A; Blackman MA
    J Virol; 2010 Mar; 84(6):2881-92. PubMed ID: 20053740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.
    Jia Q; Freeman ML; Yager EJ; McHardy I; Tong L; Martinez-Guzman D; Rickabaugh T; Hwang S; Blackman MA; Sun R; Wu TT
    J Virol; 2010 Mar; 84(5):2453-65. PubMed ID: 20015983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ T cells specific for a model latency-associated antigen fail to control a gammaherpesvirus in vivo.
    Smith CM; Rosa GT; May JS; Bennett NJ; Mount AM; Belz GT; Stevenson PG
    Eur J Immunol; 2006 Dec; 36(12):3186-97. PubMed ID: 17109468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68.
    Aricò E; Monque DM; D'Agostino G; Moschella F; Venditti M; Kalinke U; Allen DJ; Stewart JP; Nash AA; Belardelli F; Ferrantini M
    Vaccine; 2011 May; 29(23):3935-44. PubMed ID: 21481326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of cell lines latently infected with non-oncogenic murine gammaherpesvirus 76.
    Hrabovská Z; Chalupková A; Cipková J; Mistríková J
    Acta Virol; 2010; 54(4):287-91. PubMed ID: 21175252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified Vaccinia Virus Ankara Can Induce Optimal CD8
    Wong YC; Croft S; Smith SA; Lin LCW; Cukalac T; La Gruta NL; Drexler I; Tscharke DC
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31375596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice.
    Liu L; Usherwood EJ; Blackman MA; Woodland DL
    J Virol; 1999 Dec; 73(12):9849-57. PubMed ID: 10559297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-interferon activity of conserved viral dUTPase ORF54 is essential for an effective MHV-68 infection.
    Leang RS; Wu TT; Hwang S; Liang LT; Tong L; Truong JT; Sun R
    PLoS Pathog; 2011 Oct; 7(10):e1002292. PubMed ID: 21998588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency.
    Wu TT; Usherwood EJ; Stewart JP; Nash AA; Sun R
    J Virol; 2000 Apr; 74(8):3659-67. PubMed ID: 10729142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine protection against murid herpesvirus-4 is maintained when the priming virus lacks known latency genes.
    Lawler C; Simas JP; Stevenson PG
    Immunol Cell Biol; 2020 Jan; 98(1):67-78. PubMed ID: 31630452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine gammaherpesvirus 68 glycoprotein 150 does not contribute to latency amplification in vivo.
    Ruiss R; Ohno S; Steer B; Zeidler R; Adler H
    Virol J; 2012 Jun; 9():107. PubMed ID: 22681851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection.
    Rickabaugh TM; Brown HJ; Martinez-Guzman D; Wu TT; Tong L; Yu F; Cole S; Sun R
    J Virol; 2004 Sep; 78(17):9215-23. PubMed ID: 15308716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara.
    Staib C; Kisling S; Erfle V; Sutter G
    J Gen Virol; 2005 Jul; 86(Pt 7):1997-2006. PubMed ID: 15958679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The small noncoding RNAs (sncRNAs) of murine gammaherpesvirus 68 (MHV-68) are involved in regulating the latent-to-lytic switch in vivo.
    Steer B; Strehle M; Sattler C; Bund D; Flach B; Stoeger T; Haas JG; Adler H
    Sci Rep; 2016 Aug; 6():32128. PubMed ID: 27561205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of murine gamma-herpesvirus infection.
    Nash AA; Dutia BM; Stewart JP; Davison AJ
    Philos Trans R Soc Lond B Biol Sci; 2001 Apr; 356(1408):569-79. PubMed ID: 11313012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection.
    Aricò E; Robertson KA; Belardelli F; Ferrantini M; Nash AA
    Vaccine; 2004 Mar; 22(11-12):1433-40. PubMed ID: 15063566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.